Changes in inpatient treatment of Clostridioides difficile infection in a US electronic health record network, 2019–2025
Objective: To describe inpatient Clostridioides difficile infection (CDI) treatment, factors associated with fidaxomicin selection, and discharge prescribing. Design: Retrospective cohort study. Setting: A US electronic health record network, 2019–2025. Patients: Adults with CDI-coded hospital admissions supported by a qualifying laboratory result or enteral treatment. Methods: We described treatment for every study year, including multiple-agent regimens and absent treatment capture. Post-June 2021 analyses compared fidaxomicin and enteral-vancomycin recipients, adjusted for patient characteristics and calendar quarter, and examined discharge prescriptions. Sensitivities considered recorded data sources, laboratory support, and recurrence ascertainment. Results: Analyses included 507,855 episodes. Initial fidaxomicin use increased from 4.4% in 2019 to 18.9% in 2025; enteral vancomycin remained predominant (76.5% in 2025). No qualifying initial treatment was captured in 15.5% and 6.3%, respectively. Among 262,592 post-update episodes meeting treatment-timing criteria, prior CDI, immunocompromising-condition codes, and transplant codes were associated with fidaxomicin selection; these associations persisted after source adjustment. Among 43,394 surviving, valid-stay episodes initially receiving fidaxomicin alone, 5,256 (12.1%) had a vancomycin-only discharge prescription; 28.4% had no qualifying outpatient prescription captured. Recorded recurrence depended on the definition and follow-up denominator. Conclusions: Fidaxomicin uptake increased, but enteral vancomycin remained predominant. Transitions from initial fidaxomicin to vancomycin at discharge highlight a care-transition question without establishing insurance-related causation. These data describe prescribing and ascertainment, not guideline effectiveness or comparative drug benefit.
Authors
- Todd Michael Lasco (ORCID: https://orcid.org/0000-0002-5405-7067)
- Mayar Al Mohajer (ORCID: https://orcid.org/0000-0002-0333-1070)
- Shreya Jain (ORCID: https://orcid.org/0009-0005-9661-2355)
- Angela X. Wu
- Mujeeb A. Basit
Institutions
- Baylor College of Medicine (US)
- University of Oxford (GB)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Antimicrobial Stewardship & Healthcare Epidemiology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1017/ash.2026.10963
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.00